Axsome Therapeutics Inc

AXSM

NASDAQ. Currency in USD

75.81 -2.59 ( -3.30% )

Real time prices: December 19

Market Cap.
3.29B
Beta (5Y monthly)
1.86
Price/Earnings
-
EPS (TTM)
-4.02
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
974,200
1y Target Est.
104.71
Day's Range
74.79
-
79.10
52 Week's Range
20.63
-
82.00

Historical Summary

Performance
EPS growth
Share Buybacks

About Axsome Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.axsome.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
37.69M
Employees
352
Address
22 Cortlandt Street, New York, NY, United States, 10007
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Latest news

Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.
Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.

Stocks usually go down during recessions, but long-term investors can still come out on top.
By The Motley Fool - 6 weeks ago

After Jumping 100%, Is Axsome a Buy Before 2023?
After Jumping 100%, Is Axsome a Buy Before 2023?

Axsome's revenue story is just getting started.
By The Motley Fool - 6 weeks ago

Is Anavex Life Sciences a Buy?
Is Anavex Life Sciences a Buy?

It still needs to prove that its lead program is as effective as it claims...
By The Motley Fool - 6 weeks ago

Where to Invest $1,000 Before the End of 2022
Where to Invest $1,000 Before the End of 2022

Right now is the perfect time to put your money to work.
By The Motley Fool - 6 weeks ago

3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way
3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way

An economic downturn shouldn't hurt these stocks.
By The Motley Fool - 6 weeks ago

3 Medical Stocks With Solid Growth Drivers to Keep Track Of
3 Medical Stocks With Solid Growth Drivers to Keep Track Of

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the...
By Zacks Investment Research - 7 weeks ago

3 Red-Hot Stocks That Could Continue to Beat the Market
3 Red-Hot Stocks That Could Continue to Beat the Market

The success these stocks achieved in 2022 could be just the beginning.
By The Motley Fool - 7 weeks ago

3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023
3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023

These stocks' tailwinds should continue blowing in the new year.
By The Motley Fool - 7 weeks ago